Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670189 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
A Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 3
- Study locations
NCT00670189 is a Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 53 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00670189, a Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
Conditions Studied
Interventions
- DRUG BMS-833923 (XL139)
Study Locations (3)
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- Southwest Texas Addiction Research And Tech (Start) Center - San Antonio
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670189
The ClinicalTrials.gov registry entry for NCT00670189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Basal Cell Carcinoma (BCC) appearing as the primary indexed condition, and to 1 intervention - of which BMS-833923 (XL139) is the first listed.
NCT00670189 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT00670189 about?
NCT00670189 is a clinical study titled "A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer". The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
What is the current status of trial NCT00670189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2008-07. Estimated completion is 2014-05.
What conditions does trial NCT00670189 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma (BCC), Hedgehog Pathway, Smoothened, Basal Cell Nevoid Syndrome (BCNS).
What interventions are being tested in trial NCT00670189?
The interventions under investigation include: BMS-833923 (XL139) (DRUG).
Who is sponsoring clinical trial NCT00670189?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00670189 being conducted?
This trial has 3 study locations across Minnesota, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma (BCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.